Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

As an inexpensive monolayer archetypal member of the carbon family, graphene has triggered a new ‘gold rush’ in nanotechnology for achieving unique properties that were not available in many traditional materials. Owing to these unique features, graphene-related materials are finding new uses in nanomedicine and synthetic biology in addition to their diverse applications in electronics, optoelectronics, photonics and environmental clean-up. The increased production of graphene nanostructures and increased likelihood of exposures to these substances in environmental and occupational settings has raised concerns about adverse health outcomes. In particular, the biological effects of these materials need to be assessed to ensure risk free, sustainable development of graphene for widespread applications. In this work, for the first time, we studied the in vitro and in vivo interactions of a relatively new derivative of graphene, graphene nanopores (GNPs) in mammalian systems, to systematically elucidate the possible mechanism of their toxicity over time. This study showed that GNPs induced early apoptosis in both SKMES-1 and A549 lung cancer cells. However, late apoptosis is only induced at concentrations higher than 250 μg/ml, suggesting that, although GNPs at lower concentrations induce upregulation of phosphatidylserine on the cell surface membrane (i.e. early apoptotic event), GNPs do not significantly disintegrate the cell membrane. We also showed that rats intraperitoneally injected with GNPs suffered sub-chronic toxicity in a period of 27 days when tested at single and multiple doses of GNPs (5 and 15 mg/kg) as evidenced by blood biochemistry, organo-somatic index, liver and kidney enzymes functions analysis, oxidative stress biomarkers and histological examinations. In sum, our results show that GNPs are likely to have a low bioavailability in SKMES-1 and A549 lung cancer cells and rats. Nevertheless, this must be considered against the context of a wider lack of knowledge regarding the bioavailability, fate and behaviour of this type of new porous framework of graphene in natural systems. Therefore, a more long-term GNPs exposure regime, more relevant to real-life environmental consequences, is needed to fully determine the transport capacities of GNPs in living systems.

Original publication

DOI

10.1016/j.apmt.2018.07.005

Type

Journal

Applied Materials Today

Publication Date

01/09/2018

Volume

12

Pages

389 - 401